- Our Company
- News & Events
- Contact Us
Breast cancer is the most common cancer in women worldwide. To address this issue, Guardant Health AMEA has increased access of the Guardant360® test to 41 countries in Asia, Middle East and Africa. Our FDA-approved liquid biopsy can find actionable mutations in advanced cancer patients within 7 days from sample receipt in the laboratory, helping patients to access appropriate treatment quickly and safely.
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at firstname.lastname@example.org or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.